Biolinerx Ltd ADR (BLRX) Stock Price, Quote & News

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 642 9100

Fax: 972 8 642 9101

Website: www.biolinerx.com

Address:

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel

gargoyl Jul. 31 at 11:24 PM

$BLRX long the 🦋 Buy the dip.. DD says different 👇suppressing cancer in 3 ways .. PDAC 👀 data

0 · Reply

DiaJay Jul. 31 at 5:41 PM

$BLRX Such a sorry state of affairs at BLRX. No prospects, no smoke & mirrors, just sadness.

1 · Reply

Lstreak Jul. 31 at 4:57 PM

$BLRX Serlin you are through using U.S. investors to line your pockets. If you believe so much in your shitty bio stock take some of your own money and invest in it. You are the worst CEO ever!! U.S. investors have had enough!! HC Wainwright ratings are also a joke!! Wouldn't invest another nickel until CEO and entire management team is replaced.

0 · Reply

gargoyl Jul. 31 at 2:48 PM

$BLRX 🐎 👀 averaging in yet again 👂 hear $VSTM 🐎 👇Race still on since PDAC data at Asco

0 · Reply

ADAMSFBAYINVESTOR Jul. 30 at 11:39 PM

$CVNA $PSTV @Love_To_Learn Hey Mo this is what you promised to PSTV 4 years ago $20 pre split. I listened to you and invested $100K in PSTV and now I'm at -95% lost. I got wiped out $20K in MTP after 3 RS then changed name to BDRX. Also lost almost $50K in $BLRX. So how are you going to explained to your followers?

1 · Reply

gargoyl Jul. 30 at 2:55 PM

$BLRX $BMY $REGN 👇

0 · Reply

gargoyl Jul. 30 at 1:56 PM

$BLRX MM can’t contain his book, we pop .. Watch and learn , manipulation eventually finds its level, like water. 🥷🏿 Phil $BMY $REGN Long the 🦋

0 · Reply

Baseball89 Jul. 29 at 8:32 PM

$BLRX can someone please tell me if your ordinary shares changed in January for the reverse split. So if you own 1000 shares before the split would you still own 1000 shares after the split? I'm a bit confused on these reverse splits types.

2 · Reply

gargoyl Jul. 29 at 1:33 PM

$BLRX soon , she spreads her wings.

0 · Reply

gargoyl Jul. 28 at 8:06 PM

$BLRX nice closing encompassing candle, the manipulation is so apparent, 500 shares at bell sends her from 4.04 to 4.16 MM is stretching book .. something’s brewing, 2Q on deck tomorrow we rip, ignore 🤡

0 · Reply

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30, 2025, 7:00 AM EDT - 2 months ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 27, 2025, 12:55 PM EDT - 2 months ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

May 27, 2025, 7:00 AM EDT - 2 months ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 20, 2025, 7:00 AM EDT - 2 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Mar 31, 2025, 10:52 AM EDT - 4 months ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:00 AM EDT - 4 months ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:00 AM EDT - 4 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Jan 21, 2025, 7:00 AM EST - 6 months ago

BioLineRx Issues Letter to Shareholders

Jan 17, 2025, 7:00 AM EST - 7 months ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 6, 2025, 2:01 PM EST - 7 months ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Jan 6, 2025, 8:57 AM EST - 7 months ago

BioLineRx Announces $10 Million Registered Direct Offering

Nov 25, 2024, 10:58 AM EST - 8 months ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Nov 25, 2024, 7:00 AM EST - 8 months ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 21, 2024, 6:30 AM EST - 9 months ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 20, 2024, 7:19 AM EST - 9 months ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 5, 2024, 9:00 AM EST - 9 months ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Oct 16, 2024, 7:00 AM EDT - 10 months ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Sep 17, 2024, 1:01 PM EDT - 11 months ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Aug 15, 2024, 3:03 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 28, 2024, 5:56 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 6, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 1, 2024, 9:00 AM EDT - 1 year ago

BioLineRx Announces $6 Million Registered Direct Offering

Mar 26, 2024, 11:38 AM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

Mar 4, 2024, 7:00 AM EST - 1 year ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Feb 28, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 16, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Dec 21, 2023, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 4, 2023, 6:42 PM EST - 1 year ago

BioLineRx: Still A Buy, With Some Questions

Dec 2, 2023, 11:25 PM EST - 1 year ago

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges

Nov 20, 2023, 1:54 PM EST - 1 year ago

BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript

Nov 20, 2023, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Nov 13, 2023, 7:00 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Oct 31, 2023, 9:00 AM EDT - 1 year ago

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Oct 12, 2023, 7:00 AM EDT - 1 year ago

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment

Sep 28, 2023, 7:00 AM EDT - 2 years ago

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)

Sep 19, 2023, 7:00 AM EDT - 2 years ago

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

Sep 18, 2023, 1:28 AM EDT - 2 years ago

Assessing BioLineRx As A Buy After Drug Approval

gargoyl Jul. 31 at 11:24 PM

$BLRX long the 🦋 Buy the dip.. DD says different 👇suppressing cancer in 3 ways .. PDAC 👀 data

0 · Reply

DiaJay Jul. 31 at 5:41 PM

$BLRX Such a sorry state of affairs at BLRX. No prospects, no smoke & mirrors, just sadness.

1 · Reply

Lstreak Jul. 31 at 4:57 PM

0 · Reply

gargoyl Jul. 31 at 2:48 PM

$BLRX 🐎 👀 averaging in yet again 👂 hear $VSTM 🐎 👇Race still on since PDAC data at Asco

0 · Reply

ADAMSFBAYINVESTOR Jul. 30 at 11:39 PM

1 · Reply

gargoyl Jul. 30 at 2:55 PM

$BLRX $BMY $REGN 👇

0 · Reply

gargoyl Jul. 30 at 1:56 PM

$BLRX MM can’t contain his book, we pop .. Watch and learn , manipulation eventually finds its level, like water. 🥷🏿 Phil $BMY $REGN Long the 🦋

0 · Reply

Baseball89 Jul. 29 at 8:32 PM

2 · Reply

gargoyl Jul. 29 at 1:33 PM

$BLRX soon , she spreads her wings.

0 · Reply

gargoyl Jul. 28 at 8:06 PM

0 · Reply

DiaJay Jul. 25 at 11:00 PM

$BLRX Adding to BLRX be like….

0 · Reply

TwongStocks Jul. 25 at 8:37 PM

$BLRX Prospectus field this afternoon which updates their ATM. https://www.sec.gov/Archives/edgar/data/1498403/000117891325002463/zk2533477.htm So far they raised approx $3.2m under the ATM since its inception. Currently have $4.87m remaining from the ATM.

0 · Reply

gargoyl Jul. 25 at 2:21 PM

$BLRX 👀 so so coiled .. - more coiled than 🐻 trap - more coiled than mouse trap - snake 🐍 strike coiled - torque on this chart can’t hold much longer - minimal volume 10% - med volume 20% - over million volume $7.77 Target 🎯 this year $12 after $24 Why? - quiet since 1Q , 2Q ( Aug 30th) surprise 🐈‍⬛ alist - 25M cash on hand low burn 3M qt - runway 2026 - Gloria & Arymid partners - rev & 🐈‍⬛ - Ace hole PDAC data ( 40% enrollment 2026 data read out .. - $REGN collaborator Peeps 🐥 at $BMY oncology thrust 👀 Longest the 🦋

0 · Reply

TenaciousG34 Jul. 25 at 9:13 AM

$BLRX 👀

1 · Reply

Future18 Jul. 24 at 2:22 PM

$BLRX Bueller?

0 · Reply

gargoyl Jul. 23 at 7:07 PM

$BLRX $VSTM Yep

0 · Reply

gargoyl Jul. 23 at 4:47 PM

$BLRX - - (👀 ;” : : ~: _ / \_

0 · Reply

gargoyl Jul. 23 at 3:11 PM

$BLRX 👀 15k volume up 5% , looking for momentum volume to cut this hard up, MM book stretched, no more stone walling , watch her pop to 5.06 and then run 🏃‍♀️

0 · Reply

gargoyl Jul. 23 at 2:24 PM

$BLRX 👀 Is today the day 🏃 …… 🦍 ……. 💣 …. ⚡️ PDAC cancer data strong , tumors, SCD Cash on hand, pipeline , partners Gloria & Ayrmid revenue and 🐈‍⬛ alists ….. Phil rules space this year … $BMY $VSTM

1 · Reply

gargoyl Jul. 23 at 2:08 PM

$BLRX A man of his word 🥷🏿 BiloneRx is on track .. Target 🎯 $12.50 this year , $24 after $CRSP $REGN Longest the 🦋

0 · Reply

gargoyl Jul. 18 at 2:16 PM

$CRSP 🐎 insider buying $BLRX 🐎 PDAC Bullish on both

0 · Reply

gargoyl Jul. 18 at 1:19 PM

$BLRX 👀 Hope , doubt, and seem are the tools now of doubtful posts … The trend from April low of 2.30 has been overlooked, the power of PDAC on top of the foundation of minimum expenses ignored , Time to average in .. Longest the 🦋 takes the other side of the trade of below posters on feelings and fear. $XBI $IBB

0 · Reply

Market Cap	16.97M
Revenue (ttm)	28.94M
Net Income (ttm)	-9.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	50.12
Profit Margin	-31.86%
Debt to Equity Ratio	0.59

Volume	17,800
Avg Vol	852,874
Day's Range	N/A - N/A
Shares Out	4.26M
Stochastic %K	15%
Beta	1.25
Analysts	Strong Sell
Price Target	$26.00